Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2165/00003495-200666080-00008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A review of amphetamine extended release once-daily options for the management of attention-deficit hyperactivity disorder.
Expert Rev Neurother
April 2024
Division of Developmental-Behavioral Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA.
Introduction: Amphetamine preparations are one of the two categories of stimulant medications approved for the treatment of attention deficit hyperactivity disorder (ADHD). Optimal treatment of ADHD aims to reduce core symptoms for as much of the waking hours as possible, leading to longer-acting delivery formats. In addition, the pediatric population commonly has difficulty swallowing pills and manufacturers have developed a variety of options to facilitate this concern.
View Article and Find Full Text PDFEfficacy and safety of selegiline across different psychiatric disorders: A systematic review and meta-analysis of oral and transdermal formulations.
Eur Neuropsychopharmacol
July 2023
Clinical Section of Psychiatry and Psychology - Department of Neuroscience, Reproductive Sciences, and Odontostomatology, University School of Medicine Federico II, Naples, Italy; Laboratory of Molecular and Translational Psychiatry, University School of Medicine Federico II, Naples, Italy.
Selegiline is an irreversible, selective type-B monoamine oxidase inhibitor (MAOI) approved for Parkison's disease-oral and major depressive disorder-transdermal formulation) resulting in non-selective MAOI activity at oral doses≥20 mg/day. The present systematic review and meta-analysis appraises the evidence of different formulations/dosages of selegiline across different psychiatric conditions. We inquired PubMed/MEDLINE/Cochrane-Central/WHO-ICTRP/Clarivate-WebOfScience and the Chinese-Electronic-Journal Database from inception to 10/26/2022 for selegiline trials involving psychiatric patients.
View Article and Find Full Text PDFSystematic review of transdermal treatment options in attention-deficit/hyperactivity disorder: implications for use in adult patients.
CNS Spectr
April 2021
Department of Child and Adolescent Psychiatry and Psychotherapy, Johannes Gutenberg University of Medicine, Mainz, Germany.
Background: Adults with attention-deficit/hyperactivity disorder (ADHD) often face delays in diagnosis and remain untreated, despite significant negative impacts. To evaluate the safety and efficacy of transdermal treatment options in children, adolescents, and adults, a systematic literature review was conducted, with a focus on the implications of transdermal therapies for ADHD in adults.
Methods: A MEDLINE/Embase/BIOSIS/SCOPUS database search was conducted December 4, 2019, for English-language articles of interventional clinical trials using transdermal formulations for the treatment of ADHD without publication date limit.
Patch Problems? Characteristics of Transdermal Drug Delivery System Exposures Reported to the National Poison Data System.
J Med Toxicol
January 2020
Department of Emergency Medicine, University of California- San Francisco-Fresno, Fresno, CA, 93701, USA.
Background: Transdermal drug delivery systems (TDDS) pose special risks considering a large amount of drug they contain and their modified release properties. We sought to characterize TDDS exposures reported to the National Poison Data System (NPDS).
Methods: NPDS was searched for all human exposures to a TDDS from 1/1/2006 to 12/31/2015.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!